KR890006218A - 심장혈관계 질병치료용 투약기 - Google Patents

심장혈관계 질병치료용 투약기 Download PDF

Info

Publication number
KR890006218A
KR890006218A KR1019880012536A KR880012536A KR890006218A KR 890006218 A KR890006218 A KR 890006218A KR 1019880012536 A KR1019880012536 A KR 1019880012536A KR 880012536 A KR880012536 A KR 880012536A KR 890006218 A KR890006218 A KR 890006218A
Authority
KR
South Korea
Prior art keywords
osmotic
component
molecular weight
izradipine
dosage
Prior art date
Application number
KR1019880012536A
Other languages
English (en)
Other versions
KR950010151B1 (ko
Inventor
아이에트 아툴다브다트
스웬손 다비드 알
엘. 쿡진스키 안토니
Original Assignee
에드워드 엘. 맨델
알자 코포레이숀
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에드워드 엘. 맨델, 알자 코포레이숀 filed Critical 에드워드 엘. 맨델
Publication of KR890006218A publication Critical patent/KR890006218A/ko
Application granted granted Critical
Publication of KR950010151B1 publication Critical patent/KR950010151B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

심장혈관계 질병치료용 투약기
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 온혈동물의 위장관 이즈라디핀 수용체로 구강을 통하여 이즈라디핀을 투약하도록 하는데 적합하며 그에 따르는 형태를 하는 투약기.
제2도는 투약기의 내부구조를 설명하는 제1도 투약기의 개방도.
제3도는 투약기로부터 일정기간동안 시간마다 방출되는 이즈라디핀의 투약량을 도시한 그래프.
제4도는 32시간까지 연장된 시간동안 투약기에 의해 투약되는 이즈라디핀의 축적된 양을 도시한 그래프.

Claims (13)

  1. 효과가 있을 생물학적 체내 환경부위로 이즈라디핀을 투약하기 위한 심투성 투약기에 있어서, (A)이즈라디핀의 투약량과 분자량이 약 200,000인 폴리에틸렌 산화물을 포함하는 제1성분, (B)약 5,000,000 내지 7,800,000의 분자량을 갖는 폴리에틸렌 산화물 포함의 제2성분, (C)적어도 부분적으로는 사용중인 체내 환경내에 존재하는 외부유체의 통과에 대해 침투성이 있는 성분을 포함하는 벽을 포함하여, 이같은 벽이 제1 및 제2 성분을 둘러싸고, 그리고 (D)사용중인 환경으로 이즈라디핀을 전달시키기 위해 투약제의 외부를 투약제의 내부와 연결시키는 적어도 하나의 통로를 벽내에 포함함을 특징으로 하는 투약기.
  2. 제1항에 있어서, 제1 성분이 평균분자량 9,000 내지 15,000인 하이드록시프로필메틸셀룰로즈를 포함함을 특징으로 하는 삼투성 투약기.
  3. 제1항에 있어서, 제2 성분이 평균분자량 9,000 내지 15,000인 하이드록시프로필메틸셀룰로우즈를 포함함을 특징으로 하는 삼투성 투약기.
  4. 제1항에 있어서, 제2 성분이 오즈마전트(osmagent)를 포함함을 특징으로 하는 삼투성 투약기.
  5. 효과가 있는 생물학적 체내 환경부위로 이즈라디핀을 투약하기 위한 삼투성 투약기에 있어서, (A)이즈라디핀의 투약량과 분자량이 약 300,000인 톨리에틸렌 산화물을 포함하는 제1성분, (B)약 5,000,000 내지 7,800,000의 분자량을 갖는 폴리에틸렌 산화물 포함의 제2성분, (C)적어도 부분적으로는 사용중인 체내 환경내에 존재하는 외부유체의 통과에 대해 침투성이 있는 성분을 포함하는 벽을 포함하여, 이같은 벽이 제1 및 제2 성분을 둘러싸고, 그리고 (D)사용중인 환경으로 이즈라디핀을 전달시키기 위해 투약제의 외부를 투약재의 내부와 연결시키는 적어도 하나의 통로를 벽내에 포함함을 특징으로 하는 투약기.
  6. 제5항에 있어서, 제1 성분이 평균분자량 9,000 내지 15,000인 하이드록시프로필메틸셀룰로우즈를 포함함을 특징으로 하는 삼투성 투약기.
  7. 제5항에 있어서, 제2 성분이 평균분자량 9,000 내지 15,000인 하이드록시프로필메틸셀룰로우즈를 포함함을 특징으로 하는 삼투성 투약기.
  8. 제5항에 있어서, 제2 성분이 삼투압에 의해 영향을 받는 용질을 포함함을 특징으로 하는 삼투성 투약기. 평균분자량 9,000 내지 15,000인 하이드록시프로필메틸셀룰로우즈를 포함함을 특징으로 하는 삼투성 투약기.
  9. 온혈동물로 이즈라디핀을 투약하기 위한 삼투성 투약기에 있어서, (A)이즈라디핀, 분자량이 약 200,000인 톨리에틸렌 산화물, 그리고 분자량이 약 300,000인 폴리에틸렌 산화물 포함의 제1 가로막(얇은층), (B)분자량이 약 5,000,000 내지 7,800,000인 폴리에틸렌 산화물 포함의 제2가로막, (C)제1성분과 제2성분을 둘러싸며, 유체통과에 대하여 적어도 부분적으로 침투가 가능한 성분을 포함하는 벽, 그리고 (D)온혈동물로 이즈라디핀을 전달시키기 위해 벽내에 적어도 하나의 출구수단을 포함함을 특징으로 하는 삼투성 투약기.
  10. 제9항에 있어서, 제1가로막이 하이드록시프로필 메틸셀쿨로우즈를 포함함을 특징으로 하는 삼투성 투약제.
  11. 제9항에 있어서, 제2가로막이 하이드록시프로필 메틸셀룰로우즈를 포함함을 특징으로 하는 삼투성 투약제.
  12. 제9항에 있어서, 제2가로막이 삼투압에 의해 영향을 받는 화합물을 포함함을 특징으로 하는 삼투성 투약제.
  13. 단위시간당 측정된 방출속도로 약제를 투약하기 위한 삼투성 기구에 있어서, (A)유체의 통과에 대해 적어도 일부가 침투가 가능한 성분으로 되어 있는 벽을 포함하고, 이때의 벽이 (B)격실, (C)격실내에 존재하는 약제를 삼투성 기구로부터 전달시키기 위해 삼투성기구의 외부를 격실과 연결시키기 위한 벽내의 출구수단을 둘러싸고 이들을 형성시키는 것으로서, (D)상기에서와 같은 격실내에 폴리에틸렌 산화물을 포함하며, 폴리에틸렌 산화물이 약 5,000,000 내지 7,800,000의 분자량을 갖고, 단위시간당 측정된 방출속도로 약제를 투약시키기 위해 삼투성 기구와 형동하기 위한 수단임을 특징으로 하는 삼투성 기구.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880012536A 1987-10-02 1988-09-28 개량된 이즈라디핀 투약제 KR950010151B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US104,006 1987-10-02
US07/104,006 1987-10-02
US07/104,006 US4816263A (en) 1987-10-02 1987-10-02 Dosage form for treating cardiovascular diseases comprising isradipine

Publications (2)

Publication Number Publication Date
KR890006218A true KR890006218A (ko) 1989-06-12
KR950010151B1 KR950010151B1 (ko) 1995-09-11

Family

ID=22298196

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880012536A KR950010151B1 (ko) 1987-10-02 1988-09-28 개량된 이즈라디핀 투약제

Country Status (22)

Country Link
US (1) US4816263A (ko)
JP (1) JP2590235B2 (ko)
KR (1) KR950010151B1 (ko)
AT (1) AT402689B (ko)
AU (1) AU615215B2 (ko)
BE (1) BE1001101A5 (ko)
CA (1) CA1317550C (ko)
CH (1) CH677609A5 (ko)
DE (1) DE3833282C2 (ko)
DK (1) DK175564B1 (ko)
ES (1) ES2011120A6 (ko)
FI (1) FI92554C (ko)
FR (1) FR2622798B1 (ko)
GB (1) GB2210266B (ko)
IE (1) IE61862B1 (ko)
IT (1) IT1234215B (ko)
LU (1) LU87351A1 (ko)
NL (1) NL194748C (ko)
NO (1) NO176466C (ko)
PT (1) PT88618B (ko)
SE (1) SE503471C2 (ko)
ZA (1) ZA887362B (ko)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946687A (en) * 1987-10-02 1990-08-07 Alza Corporation Dosage form for treating cardiovascular diseases
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US6124355A (en) * 1995-05-22 2000-09-26 Guittard; George V. Oxybutynin therapy
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US6238697B1 (en) 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1404324B2 (en) * 2001-06-11 2011-04-06 XenoPort, Inc. Prodrugs of gaba analogs, compositions and uses thereof
JP2005501013A (ja) * 2001-06-11 2005-01-13 ゼノポート，インコーポレイテッド Ｇａｂａ類似体の全身濃度が持続するアミノ酸コンジュゲート
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6524618B1 (en) 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
WO2004053192A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
EP1608357A4 (en) * 2003-03-31 2008-03-26 Xenoport Inc TREATMENT OR PREVENTION OF HITZEWALLUNGEN USING PRODRUGS OF GABA ANALOGUE
PT1660440E (pt) * 2003-08-20 2012-05-15 Xenoport Inc Pró-fármacos de aciloxialquilcarbamato, métodos de síntese e utilização
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
US7700652B2 (en) * 2003-09-11 2010-04-20 Xenoport, Inc. Treating urinary incontinence using prodrugs of GABA analogs
EP1677812A4 (en) * 2003-09-17 2010-03-24 Xenoport Inc TREATMENT OR PREVENTION OF NON-REST LEG SYNDROME USING GABA ANALOGUE-BASED PRODRUGS
US20060128676A1 (en) * 2004-07-13 2006-06-15 Pharmacofore, Inc. Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain
US7566738B2 (en) * 2004-11-03 2009-07-28 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
US7494985B2 (en) * 2004-11-03 2009-02-24 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
CN101068538A (zh) * 2004-11-04 2007-11-07 什诺波特有限公司 加巴喷丁前体药物持续释放口服剂型
EP1919859B1 (en) * 2005-06-20 2010-06-02 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of tranexamic acid and use
WO2007002597A2 (en) 2005-06-27 2007-01-04 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
US20070049626A1 (en) * 2005-08-26 2007-03-01 Tran Pierre V Treating premature ejaculation using gabapentin and pregabalin prodrugs
US20070128282A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
DK2046393T3 (da) 2006-05-26 2014-05-12 Signature Therapeutics Inc Kontrolleret frigivelse af phenol-opioider
WO2008033572A1 (en) * 2006-09-15 2008-03-20 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
MX2009006080A (es) * 2006-12-08 2009-07-14 Xenoport Inc Uso de profarmacos de analogos de gaba para el tratamiento de enfermedades.
US7714201B2 (en) * 2006-12-22 2010-05-11 Monsanto Technology Llc Cotton variety 781000G
US7419684B2 (en) * 2006-12-22 2008-09-02 Reliant Pharmaceuticals, Inc. System and method for manufacturing oral osmotic drug delivery devices, and methods of administering same
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
WO2011028234A1 (en) * 2009-09-04 2011-03-10 Xenoport, Inc. Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
WO2012050907A2 (en) 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
CN102349880B (zh) * 2011-10-12 2015-07-22 合肥华方医药科技有限公司 伊拉地平控释片及其制备方法
CN105030726A (zh) * 2015-08-30 2015-11-11 四川百利药业有限责任公司 一种伊拉地平胶囊的制备方法
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
US9808452B2 (en) 2015-10-01 2017-11-07 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
CA3056239C (en) 2017-03-17 2023-09-12 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
CH639659A5 (de) * 1978-12-18 1983-11-30 Sandoz Ag Neue 1,4-dihydropyridinderivate, deren herstellung und verwendung.
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
HU198844B (en) * 1984-06-14 1989-12-28 Sandoz Ag Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
GB2181053B (en) * 1985-10-01 1990-05-23 Sandoz Ltd Pharmaceutical formulations with controlled release of the active substance
US4723957A (en) * 1986-02-07 1988-02-09 Alza Corp. System for delivering drug with enhanced bioacceptability
US4753802A (en) * 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form
AU2152888A (en) * 1987-08-25 1989-03-02 Cerra Metal Works Pty. Ltd. Masonry tie
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine

Also Published As

Publication number Publication date
DE3833282C2 (de) 1997-02-13
NO884259D0 (no) 1988-09-27
ZA887362B (en) 1989-06-28
PT88618B (pt) 1993-07-30
GB2210266B (en) 1991-07-24
BE1001101A5 (fr) 1989-07-11
US4816263A (en) 1989-03-28
GB2210266A (en) 1989-06-07
GB8822852D0 (en) 1988-11-02
FI92554B (fi) 1994-08-31
FI884526A (fi) 1989-04-03
IE61862B1 (en) 1994-11-30
DK545088A (da) 1989-04-03
NL194748B (nl) 2002-10-01
FI92554C (fi) 1994-12-12
FI884526A0 (fi) 1988-09-30
SE503471C2 (sv) 1996-06-24
IT8867880A0 (it) 1988-09-30
NL194748C (nl) 2003-02-04
CH677609A5 (ko) 1991-06-14
NO884259L (no) 1989-04-03
SE8803486L (sv) 1989-04-03
DK545088D0 (da) 1988-09-29
AU615215B2 (en) 1991-09-26
JP2590235B2 (ja) 1997-03-12
AT402689B (de) 1997-07-25
FR2622798A1 (fr) 1989-05-12
ATA242288A (de) 1996-12-15
NO176466B (no) 1995-01-02
CA1317550C (en) 1993-05-11
SE8803486D0 (sv) 1988-09-30
IT1234215B (it) 1992-05-06
DK175564B1 (da) 2004-12-06
DE3833282A1 (de) 1989-04-20
IE882960L (en) 1989-04-02
ES2011120A6 (es) 1989-12-16
JPH01113316A (ja) 1989-05-02
PT88618A (pt) 1989-07-31
NO176466C (no) 1995-04-12
FR2622798B1 (fr) 1993-10-15
AU2293888A (en) 1989-04-06
KR950010151B1 (ko) 1995-09-11
LU87351A1 (fr) 1989-04-06
NL8802401A (nl) 1989-05-01

Similar Documents

Publication Publication Date Title
KR890006218A (ko) 심장혈관계 질병치료용 투약기
KR880013586A (ko) 고체상태성질을 가진 제거 가능한 기질을 포함하는 투약기
US4693886A (en) Osmotic device with inert core
TW446552B (en) Osmotic delivery system with membrane plug retention mechanism
FI107699B (fi) Annostusmuoto lääkkeen annostelun ajan suhteen vaihtelevien mallien aikaansaamiseksi
US4210139A (en) Osmotic device with compartment for governing concentration of agent dispensed from device
NL193308C (nl) Doseervorm geschikt voor de afgifte van een preparaat van een heilzaam middel aan een gebruiksomgeving.
JP3301612B2 (ja) ローディングドースを含む長期配送デバイス
US5147654A (en) Oral osmotic device for delivering nicotine
US4474575A (en) Self-driven pump assembly and method of operation
KR870008583A (ko) 슈도에페드린, 브롬페니라민 요법
JP2773857B2 (ja) 結腸放出系浸透圧構成体
KR920703020A (ko) 히드로겔 드라이빙 부재를 갖는 구강 삼투 장치
KR920703066A (ko) 경구용 혈당강하제인 글리피자이드의 투여를 위한 제형
KR890000081A (ko) O차 조절된 약물 전달 시스템
KR890004684A (ko) 신속 방출제 전달계와 완속 방출제 전달계로 된 제형(劑刑)
NO923756L (no) Osmotisk doseringssystem for avgivelse av vaeskeformig medikament
PT96152A (pt) Sistema de libertacao pulsatil multi-unitario
MX2012000502A (es) Capsulas de liberacion sostenida.
KR870008594A (ko) 베라파밀제형
CA2047418A1 (en) Oral osmotic device for delivering nicotine
KR920703022A (ko) 가용성 또는 불용성 약물의 전달을 위한 제형
JPS6244249A (ja) 有効剤組成物を反芻動物に投与するための投与デイバイス
JP3399527B2 (ja) 疎水性装填薬剤を含む長期的投与デイバイス
US20060043207A1 (en) Apparatus, kit and related methods for administering substances

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20020903

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee